Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Chiron's FGF-2 misses target

CHIR said its Phase II trial of recombinant fibroblast growth factor-2 in coronary

Read the full 136 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE